Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | MIF | P14174 | 1/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.56 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15923722 | 1.00 | CA12 (0.61) | CA12CA1CA2CA9MIF | |
| SCHEMBL15060890 | 0.99 | CA12 (0.62) | CA12CA1CA2CA9MIF | |
| SCHEMBL15935943 | 0.88 | CA12 (0.58) | CA12CA1CA2CA9MIF | |
| SCHEMBL13527035 | 0.86 | MIF (0.58) | CA12CA1CA2CA9MIF | |
| SCHEMBL21157717 | 0.86 | MIF (0.58) | CA12CA1CA2CA9MIF | |
| SCHEMBL16213084 | 0.86 | MIF (0.67) | CA12CA1CA2CA9MIF | |
| SCHEMBL16220782 | 0.86 | MIF (0.63) | CA12CA1CA2CA9MIF | |
| SCHEMBL16212825 | 0.81 | MIF (0.57) | CA12CA1CA2CA9MIF | |
| SCHEMBL13527251 | 0.79 | FLT3 (0.62) | CA12CA1CA2CA9MIF | |
| SCHEMBL16212691 | 0.78 | NAMPT (0.63) | MIFS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-06-02 | — | — | US | disclosed |
| US-20100016955-A1 | Triazole compounds and methods of making and using the same | BioVersys AG (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016955-A1 | Triazole compounds and methods of making and using the same | IL33, PROKR1, VIP | CA12 3772/4885CA1 3327/4885CA2 3823/4885 |
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | CA12 4447/4885CA1 3502/4885CA2 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.